Prednicarbate An official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationBookshelfSearch databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein GroupsMedGenMeSHNLM and EffectsSummary of Use during LactationTopical prednicarbate has not been studied during breastfeeding. Since only extensive application of the most potent corticosteroids may cause systemic effects in the mother, it is unlikely that short-term application of topical corticosteroids would pose a risk to the breastfed infant by passage into breastmilk. However, it would be prudent to use the least potent drug
reevaluated: erythemogenic versus suberythemogenic ultraviolet with a tar extract in oil and crude coal tar.[J Am Acad Dermatol. 1983]Comparative chemical and biological analysis of coal tar-based therapeutic agents to other coal-derived materials.[J Appl Toxicol. 1985]Wood tars allergy, cross-sensitization and coal tar.[Contact Dermatitis. 1990]Review Prednicarbate.[Drugs and Lactation Database (...]See
LinksRelated informationPubChem SubstancePubMedSimilar articles in PubMedTreatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.[J Pharmacol Exp Ther. 2016]Review Tazarotene.[Drugs and Lactation Database (...]Review Prednicarbate.[Drugs and Lactation Database
(methylprednisolone aceponate, mometasone furoate, prednicarbate, clobetasol propionate, betamethasone 17-valerate, and betamethasone 17,21-dipropionate). Additionally, 2547 (68.8%) patients were tested with hydrocortisone 17-butyrate. Fifty-four patients showed positive reactions to at least one of all tested corticosteroids (1.46%). Thirty-nine (1.05%) reacted to at least one of the additionally tested
the therapeutic efficacy and safety of superficial cryotherapy for treatment of AA. In 19 patients with multiple bilateral AA patches on their scalp, superficial cryotherapy was performed on the right side, every 2 weeks. Prednicarbate 0.25% solution was applied twice a day to both the treated and the control sides. Clinical improvement was estimated using the Severity of Alopecia Tool (SALT) score by 3
-week period and to what extent this consumption is related to the course of the severity of patients' skin conditions. Thirty adult outpatients (20 female and 10 male) with atopic dermatitis were examined at four different times during 26 weeks. For treatment and skin care these patients were given a topical glucocorticoid preparation (prednicarbate) and the corresponding emollient. The average severity rating (SCORAD) was 29.6 (before therapy 33.9, after 26 weeks 27.4). The SCORAD indices improved by a mean of 6.5 points (p<0.05). Patients who applied the correct amount of the prednicarbate-containing preparations (not less than 90% of 0.5 g/dm(2)) to the areas of affected skin showed a significant improvement in SCORAD indices across the four measuring times.
after repeated open application of 0.1% betamethasone 17-valerate cream and 0.25% prednicarbate cream, but an increase following the vehicle of the latter preparation. Thus commercial oil-in-water emulsion preparations seem to be potentially injurious to human skin, though this may be masked when a glucocorticoid is added.
[Treatment of impetiginized eczema with prednicarbate in combination with a quarternary ammonium salt]. After a brief account of the therapeutic problems with microbially superinfected eczemas, the results of a double-blind study of hospitalized patients are reported. Two concentrations of the antibacterial agent Bardac-22 (didecyl-dimethyl-ammonium chloride. Hoe S 2922) in combination with the steroid prednicarbate (prednisolone 17-(ethylcarbonate)-21-propionate, Hoe 777) were used. The quantitative determination of cutaneous bacteria was performed by a modified method of Faergemann. The double blind study did not reveal any significant differences in effectiveness, although a trend in favour of the higher concentration was apparent.
systemic and local, especially skin atrophy. The purpose of this study was to assess the atrophogenicity potential of newly developed topical glucocorticoids which were said to show an increased benefit-risk ratio. The test preparations comprised mometasone furoate, the corresponding vehicle, prednicarbate and hydrocortisone. They were applied once or twice daily for 6 weeks in healthy volunteers. Skin thickness was assessed weekly by using high frequency pulsed ultrasound. Clinically, none of the volunteers showed any sign of overt skin atrophy. Skin thickness, however, was reduced to a certain extent with all trial preparations including the base preparation. As to be expected from previous experiments the results for hydrocortisone and prednicarbate did not differ significantly from the ones
(cream, ointment and fatty ointment) has been related to those of the respective vehicles as well as commercially available preparations of five corticosteroids: betamethasone 17,21-dipropionate 0.64% (BDP), betamethasone 17-valerate 0.1% (BV), clobetasol 17-propionate 0.05% (CP), hydrocortisone 17-butyrate 0.1% (HCB), prednicarbate 0.25% (P). In each experiment, MPA activity significantly exceeded
Modern topical glucocorticoids and anti-infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination? The addition of an anti-infective to a topical glucocorticoid preparation for superinfected atopic eczema is still controversial. To address this question in the context of the topical glucocorticoids of the non-halogenated double -ester type 0.25% prednicarbate cream was compared to the identical preparation incorporating the same amount of the disinfectant didecyldimethylammoniumchloride in patients suffering from atopic eczema carrying Staphylococcus aureus at a density of more than 10(6) colony-forming units per cm2. One of the preparations was used twice daily over 5 days according to a random plan in a blind fashion
been proposed. In a comparative trial using the DUB 20 system, 24 healthy volunteers applied hydrocortisone aceponate, the corresponding vehicle, prednicarbate ointment and betamethasone-17-valerate ointment over a period of 6 weeks. While both hydrocortisone aceponate and prednicarbate ointment induced no significant reduction in skin thickness, the onset of epidermal-dermal thinning
[Treatment of acute episodes of atopic dermatitis. Double-blind comparative study with 0.05% halometasone cream versus 0.25% prednicarbate cream]. In a double-blind, randomized multicenter study in patients with acute episodes of atopic dermatitis, the efficacy and tolerance of 0.5% halometasone (Sicorten) cream were compared with those of 0.25% prednicarbate cream. A total of 165 patients (88 men, 77 women) were admitted to the study. The halometasone group contained 9% more cases with severe disease than did the prednicarbate group. Two daily nonocclusive applications were permitted, and treatment lasted 14 days. No difference in the onset of the effect was observed between the two groups. With respect to clinical efficacy, higher healing rates were found in the halometasone group: 50.6